Examination of the serum soluble mesothelin-related peptide (SMRP) level in patients with malignant pleural mesothelioma (Poster presentation,General Lecture) 2016/05/02
106.
Patterns of Detectable Tumor Progression in Patients with Malignant Pleural Mesothelioma with an FDG-PET-Negative T1a Tumor (Poster presentation,General Lecture) 2016/05/02
107.
Relationship between Histological Type and Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/02
108.
Induction Chemotherapy Followed by Surgery for Malignant Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/03
109.
The Analysis of the Recurrence of the Patients Who Underwent Surgical Resection for Malignant Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/03
Cisplatin in Combination for Pemetrexed in the Treatment of Patients with Advanced Malignant Peritoneal Mesothelioma -Retrospective study of 24 cases- (Poster presentation,General Lecture) 2016/10/07
PET/CT FOR PATIENTS WITH VERY EARLY CLINICAL STAGE OF MALIGNANT PLEURAL MESOTHELIOMA:WHEN CAT PET/CT DETECT TUMOR GROWTH OF TO/T1A MESOTHLIOMA? (Poster presentation,General Lecture) 2016/12/06
124.
between the stainability of the neurofibromatosis type 2 gene-related protein merlin and the tumor properties of mesotheliomas (Poster presentation,General Lecture) 2016/12/07
125.
Mesothelium Covering Pleural Plaque Is Not Primary Involved in Asbestos-Induced Mesothelial Carcinogenesis in Human (Poster presentation,General Lecture) 2016/12/07
126.
Cisplatin in Combination for Pemetrexed in the Treatment of Patients with Advanced Malignant Peritoneal Mesothelioma -Retrospective study of 24 cases (Poster presentation,General Lecture) 2016/12/16